PAYAL PATEL: Open Payments
NPI 1568927580 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$246 in 12 payments from 9 companies in 2025. Trend: 2023 $289 · 2024 $474 · 2025 $246
Food & beverage: $246
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Lundbeck LLC | 2 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| ABBVIE INC. | 1 | $23 |
| Alkermes, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: ABILIFY ASIMTUFII, CAPLYTA, INGREZZA, REXULTI, VRAYLAR, LYBALVI, LOREEV XR, GORE VIABAHN VBX Balloon Expandable Endo.
Industry payments across TX — which companies pay providers there.
